Spero Therapeutics Inc (SPRO) Stock Price, Quote & News

Company Profile

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candi...

Industry: Biotechnology

Sector: Healthcare

Phone: (857) 242-1600

Website: sperotherapeutics.com

Address:

675 Massachusetts Avenue, 14th Floor, Cambridge, United States

look2theblue Aug. 2 at 8:37 PM

$ITRM People said the same when $SPRO was at .50 then it ran to $3.22. Your are likely just paid a poster for a short position OR fund attempting to start a position. GL

1 · Reply

mdboss Aug. 2 at 9:25 AM

$SPRO I stated my case for an appropriate valuation and timing for a BO. This will happen and it will happen soon. We are talking HUGE #'s and SPRO and GSK need to get this deal right. This will easily 10x and should 20x. The market for Tebi and the impact and cost savings are monumental. Tebi is a behemoth and by any rational analysis will sell in the billions - annually! And if you think SPR720 also doesn't carry a serious value proposition, then you are sadly mistaken, IMHO.

4 · Reply

n44 Aug. 1 at 8:03 PM

$SPRO Good sideways action considering the market was down (red) all day, next week gets us closer to goal, NDA, priority review and another milestone payment from GlaxoSmithKline or maybe a buyout.

1 · Reply

DDel Aug. 1 at 6:43 PM

$SPRO “We're delighted to announce these exciting agreements with Hengrui Pharma which complement our already-extensive pipeline,” GSK Chief Scientific Officer Tony Wood, Ph.D., said. “This deal reflects our strategic investment in programs that address validated targets, increasing the likelihood of success, and with the option to advance those assets with the greatest potential for patient impact,” Wood added. GSK is hungry and globally proactive. Our deal is coming, I have no doubt whatsoever. I agree completely with Tony Wood's perspective. Our cUTI drug, will be used early on for hosp sepsis patients too, saving many lives, and insur cos a fortune, globally. I foresee massive sales for GSK. https://www.fiercebiotech.com/biotech/gsk-strengthens-copd-offering-12b-biobucks-deal-chinas-hengrui-pharma

1 · Reply

n44 Aug. 1 at 5:24 PM

$SPRO I missed what happened, there must have been some big block trades, the volume increased drastically, good sign.

0 · Reply

n44 Aug. 1 at 2:07 PM

$SPRO The market is deep Red and the stock is algo trading based on the market conditions, not big volume, just know it will bounce. I try not to do anything on Friday’s not my lucky day for stock trading.

1 · Reply

DDel Jul. 31 at 8:23 PM

$SPRO bought more today.

0 · Reply

n44 Jul. 31 at 6:26 PM

$SPRO Good trading action today, we need shares trading and changing hands, it will make the stock stronger when news comes out.

1 · Reply

n44 Jul. 31 at 5:43 PM

$SPRO Lets hope we see a million shares trading today, notice the basket of shares has gotten smaller since we cut through the 2.40 share price.

0 · Reply

Olg59 Jul. 31 at 5:16 PM

$SPRO Perfect candidate for buyout for 5-7 bucks

1 · Reply

Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results

May 28, 2025, 11:24 AM EDT - 2 months ago

Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?

GSK

May 28, 2025, 7:00 AM EDT - 2 months ago

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

GSK

May 13, 2025, 4:01 PM EDT - 2 months ago

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

May 5, 2025, 8:00 AM EDT - 3 months ago

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

Apr 28, 2025, 4:01 PM EDT - 3 months ago

Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

Mar 27, 2025, 8:31 PM EDT - 4 months ago

Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:01 PM EDT - 4 months ago

Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update

Mar 18, 2025, 8:00 AM EDT - 4 months ago

Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

Feb 25, 2025, 10:15 AM EST - 5 months ago

UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 7:00 AM EST - 5 months ago

Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Jan 19, 2025, 8:00 AM EST - 7 months ago

Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal

Jan 10, 2025, 7:00 AM EST - 7 months ago

Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

Nov 14, 2024, 4:05 PM EST - 9 months ago

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

Oct 16, 2024, 4:05 PM EDT - 10 months ago

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024

Oct 2, 2024, 4:30 PM EDT - 10 months ago

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

Aug 9, 2024, 10:47 AM EDT - 1 year ago

Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 4:01 PM EDT - 1 year ago

Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update

Jul 29, 2024, 4:05 PM EDT - 1 year ago

Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024

Jul 3, 2024, 1:05 PM EDT - 1 year ago

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 16, 2024, 4:05 PM EDT - 1 year ago

Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

May 15, 2024, 4:05 PM EDT - 1 year ago

Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update

May 8, 2024, 8:00 AM EDT - 1 year ago

Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024

May 1, 2024, 4:07 PM EDT - 1 year ago

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 23, 2024, 11:37 AM EDT - 1 year ago

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

Mar 13, 2024, 5:45 PM EDT - 1 year ago

Spero Therapeutics, Inc. (SPRO) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 4:01 PM EDT - 1 year ago

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

Mar 6, 2024, 8:05 AM EST - 1 year ago

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024

Feb 28, 2024, 8:05 AM EST - 1 year ago

Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

Feb 26, 2024, 8:05 AM EST - 1 year ago

Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference

Jan 5, 2024, 8:05 AM EST - 1 year ago

Spero Therapeutics Provides Corporate Update and 2024 Outlook

Jan 2, 2024, 8:05 AM EST - 1 year ago

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Nov 13, 2023, 7:05 PM EST - 1 year ago

Spero Therapeutics, Inc. (SPRO) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 8:05 AM EST - 1 year ago

Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Nov 1, 2023, 8:05 AM EDT - 1 year ago

Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

Sep 20, 2023, 4:05 PM EDT - 2 years ago

Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor Conference

Sep 6, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

Jul 31, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr

Jul 5, 2023, 3:06 PM EDT - 2 years ago

Spero Therapeutics: The Multi-Asset Pipeline Could Outpace The Tebipenem HBr Deal With GSK

Jun 14, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer

May 11, 2023, 8:59 PM EDT - 2 years ago

Spero Therapeutics, Inc. (SPRO) Q1 2023 Earnings Call Transcript

May 11, 2023, 4:05 PM EDT - 2 years ago

Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business Update

May 4, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

Apr 26, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics to Present at Upcoming Investor Conference

Apr 21, 2023, 4:46 PM EDT - 2 years ago

Spero Therapeutics: Massive Partnership Deal Still Not Properly Valued By The Market

Apr 14, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases

Mar 30, 2023, 10:11 PM EDT - 2 years ago

Spero Therapeutics, Inc. (SPRO) Q4 2022 Earnings Call Transcript

look2theblue Aug. 2 at 8:37 PM

$ITRM People said the same when $SPRO was at .50 then it ran to $3.22. Your are likely just paid a poster for a short position OR fund attempting to start a position. GL

1 · Reply

mdboss Aug. 2 at 9:25 AM

4 · Reply

n44 Aug. 1 at 8:03 PM

$SPRO Good sideways action considering the market was down (red) all day, next week gets us closer to goal, NDA, priority review and another milestone payment from GlaxoSmithKline or maybe a buyout.

1 · Reply

DDel Aug. 1 at 6:43 PM

1 · Reply

n44 Aug. 1 at 5:24 PM

$SPRO I missed what happened, there must have been some big block trades, the volume increased drastically, good sign.

0 · Reply

n44 Aug. 1 at 2:07 PM

1 · Reply

DDel Jul. 31 at 8:23 PM

$SPRO bought more today.

0 · Reply

n44 Jul. 31 at 6:26 PM

$SPRO Good trading action today, we need shares trading and changing hands, it will make the stock stronger when news comes out.

1 · Reply

n44 Jul. 31 at 5:43 PM

$SPRO Lets hope we see a million shares trading today, notice the basket of shares has gotten smaller since we cut through the 2.40 share price.

0 · Reply

Olg59 Jul. 31 at 5:16 PM

$SPRO Perfect candidate for buyout for 5-7 bucks

1 · Reply

n44 Jul. 31 at 5:10 PM

$SPRO We just passed 2.41 🍀🍀🍀🍀🍀🍀🍀🍀🍀🍀 Volume And Price

1 · Reply

n44 Jul. 31 at 4:39 PM

$SPRO There is no resistance once we get past 2.41 needs more volume and hopefully some news!!!!!

0 · Reply

ZManicItalian Jul. 31 at 4:08 PM

$SPRO green! Suspect until it get over $2.50 with good volume

0 · Reply

CrispDry Jul. 31 at 3:56 PM

$SPRO news today? I feel a buyout is inevitable

0 · Reply

n44 Jul. 31 at 3:48 PM

$SPRO Looks like GSK is moving the NDA along, we should get priority review this time as well!

2 · Reply

n44 Jul. 31 at 3:46 PM

$SPRO Just saw 10,000 [email protected]. Another Buy 25,000 @ 2.34 GOOD Volume with upside 🍀🍀🍀🍀🍀

3 · Reply

peapope Jul. 31 at 1:53 PM

$SPRO 2.15 bottom in?

1 · Reply

n44 Jul. 31 at 10:53 AM

$SPRO Bossmd where are you?

2 · Reply

peapope Jul. 30 at 10:53 PM

$SPRO will also note over 2mil shares covered since May top now 1.2mil short down from roughly 3.5mil glta longe

0 · Reply

peapope Jul. 30 at 10:23 PM

$SPRO not alot of stock for sale afterhours

0 · Reply

Bigos Jul. 30 at 10:01 PM

$SPRO @mdboss Where is this pumper clown hiding?

0 · Reply

Inc82 Jul. 30 at 8:58 PM

$SPRO where is the pumper who said “a deal will occur by July 31st. Still waiting for you to show up.

2 · Reply

Market Cap	128.60M
Revenue (ttm)	47.98M
Net Income (ttm)	-68.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-142.91%
Debt to Equity Ratio	0.00

Volume	518,700
Avg Vol	5,510,526
Day's Range	N/A - N/A
Shares Out	55.91M
Stochastic %K	48%
Beta	1.39
Analysts	Sell
Price Target	$5.00